Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$45.00K$45.00K−80.7% vs Q3 2021 Net Income-$9.47M-$9.47MN/M vs Q3 2021 EPS Diluted-$0.38-$0.38N/M vs Q3 2021 Operating Income-$9,799,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,788,000N/M Margins · derivedOperating margin-21775.6%−18999.2 pt vs Q3 2021
Net margin-21053.3%−18296.7 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end